Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine Extension in Vascular Dementia
NCT00130338Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2002
- Primary completion
- May 2006
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of rivastigmine in vascular dementia, sponsored by Novartis. Started Feb 2002; status: completed.
02
Drugs
rivastigmine
03
Conditions
vascular dementia
Beyond the preview
Go deeper on NCT00130338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130338.